Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer

Experimental and Therapeutic Medicine

Volumn 1, Issue 5, 2010, Pages 799-808

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Imai, Hisao ^a   Shimizu, Kimihiro ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Hisada, Takeshi ^a   Kawashima, Osamu ^b   Kamide, Yosuke ^b   Ishizuka, Tamotsu ^a   Kanai, Yoshikatsu ^c   Nakajima, Takashi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shibukawa Medical Center   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

4F2 heavy chain; L type amino acid transporter 1; Non small cell lung cancer; Stage III

Indexed keywords

AMINO ACID TRANSPORTER; CD31 ANTIGEN; CD34 ANTIGEN; CD98 ANTIGEN; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MICROVASCULATURE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 77955203324     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.117     Document Type: Article

References (38)

1. Shottenfeld D: Epidemiology of Lung Cancer. Lippincott-Raven, Philadelphia, PA, 1996.
2. Graziano SL: Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17 (Suppl 1): 37-58, 1997.
3. Mountain CF: Revision in the International System for Staging Lung Cancer. Chest 11: 1710-1717, 1997.
4. Andre F, Grunenwald D, Pignon JP, et al: Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18: 2981-2989, 2000.
5. Leong SS, Rocha Lima CM, Sherman CA and Green MR: The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest 115: 242-248, 1999.
6. Jassem J, Skokowski J, Dziadziuszko R, et al: Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119: 1141-1146, 2000.
7. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. JClin Oncol 15: 2996-3018, 1997.
8. Christensen HN: Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70: 43-77, 1990.
9. McGivan JD and Pastor-Anglada M: Regulatory and molecular aspects of mammalian amino acid transport. Biochem J299: 321-334, 1994.
10. Oxender DL and Christensen HN: Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 197: 765-767, 1963.
11. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). JBiol Chem 273: 23629-23632, 1998.
12. Yanagida O, Kanai Y, Chairoungdua A, et al: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514: 291-302, 2001.
13. Ohkame H, Masuda H, Ishii Y and Kanai Y: Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. JSurg Oncol 78: 265-272, 2001.
14. Kaira K, Oriuchi N, Imai H, et al: Prognostic significance of L-type amino acid transporter 1 expression in resectable stageI-III non small cell lung cancer. Br JCancer 98: 742-748, 2008.
15. Kaira K, Oriuchi N, Imai H, et al: Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 204: 553-561, 2008.
16. Nakanishi K, Ogata S, Matsuo H, et al: Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451: 681-690, 2007.
17. Nawashiro H, Otani N, Shinomiya N, et al: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int JCancer 119: 484-492, 2006.
18. Chairoungdua A, Segawa H, Kim JY, et al: Identification of an amino acid transporter associated with the cystinuria-related type IImembrane glycoprotein. JBiol Chem 274: 28845-28848, 1999.
19. Matsuo H, Tsukada S, Nakata T, et al: Expression of a system Lneutral amino acid transporter at the blood-brain barrier. Neuro report 11: 3507-3511, 2000.
20. Buck AC, Schirrmeister HH, Guhlmann CA, et al: Ki-67 immuno staining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? JNucl Med 42: 721-725, 2001.
21. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. NEngl JMed 324: 1-8, 1991.
22. Mineo TC, Ambrogi V, Baldi A, et al: Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for IB-II Anon-small cell lung cancer. J Clin Pathol 57: 591-597, 2004.
23. Fucks BC, Finger RE, Onan MC and Bode BP: ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 293: 55-63, 2007.
24. Kaira K, Oriuchi N, Imai H, et al: L-type amino acid transporter1 (LAT1) and CD98 expression in the primary site and the metastatic site of human neoplasms. Cancer Sci 99: 2380-2386, 2008.
25. Rintoul RC, Buttery RC, Mackinnon AC, et al: Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 13: 2841-2852, 2002.
26. Esteban F, Ruiz-Cabello F, Concha A, Perez Ayala M, DelgadoM and Garrido F: Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx. Cancer 66: 1493-1498, 1990.
27. Kaira K, Oriuchi N, Otani Y, et al: Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathological study. Clin Cancer Res 13: 6369-6378, 2007.
28. Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patient survival in lung cancer: systematic review of the literature with meta-analysis. Br JCancer 91: 2018-2025, 2005.
29. Han H, Silverman JF, Santucci TS, et al: Vascular endothelial growth factor expression in stage Inon-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001.
30. Oriuchi N, Higuchi T, Ishikita T, et al: Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 97: 1291-1297, 2006.
31. Kaira K, Oriuchi N, Otani Y, et al: Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 131: 1019-1027, 2007.
32. Inoue T, Koyama K, Oriuchi N, et al: Detection of malignant tumors: whole-body PET with fluorine-18-α-methyl tyrosine versus FDG-preliminary study. Radiology 220: 54-62, 2001.
33. Tomiyoshi K, Amed K, Muhammad S, et al: Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun 18: 169-175, 1997.
34. Kim DK, Kanai Y, Choi HW, et al: Characterization of the system Lamino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 1565: 112-122, 2002.
35. Kaira K, Oriuchi N, Shimizu K, et al: Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124: 1152-1160, 2009.
36. Kim CS, Cho SH, Chun HS, et al: BCH, an inhibitor of system Lamino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31: 1096-1100, 2008.
37. Berghmans T, Meert AP, Martin B, Ninane V and Sculier JP: Prognostic role of epidermal growth factor receptor in stage III non-small cell lung cancer. Eur Respir J25: 329-335, 2005.
38. Berghmans T, Mascaux C, Martin B, Ninane V and SculierJP: Prognostic role of thyroid transcription factor-1 in stage IIInon-small cell lung cancer. Lung Cancer 52: 219-224, 2006.